参考文献/References:
[1]Joly BS,Coppo P,Veyradier A.Thrombotic thrombocytopenic purpura[J].Blood,2017,129(21):2836-2846. [2]Saha M,McDaniel JK,Zheng XL.Thrombotic thrombocytopenic purpura:pathogenesis, diagnosis and potential novel therapeutics[J]J Thromb Haemost,2017,15(10):1889-1900.[3]中华医学会血液学分会血栓与止血学组.血栓性血小板减少性紫癜诊断与治疗中国指南(2022年版)[J].中华血液学杂志,2022,43(1):7-12.[4]Sukumar S,L?覿mmle B,Cataland SR.Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management[J].J Clin Med,2021,10(3):536.[5]Roose E,Veyradier A,Vanhoorelbeke K,et al.Insights into ADAMTS13 structure:impact on thrombotic thrombocytopenic purpura diagnosis and management[J].Curr Opin Hematol,2020,27(5):320-326. [6]Page EE,Kremer Hovinga JA,Terrell DR,et al.Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015[J].Blood,2017,1(10):590-600.[7]Kremer Hovinga JA,Heeb SR,Skowronska M,et al.Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome[J].J Thromb Haemost,2018,16(4):618-629.[8]石茂静,高伟波,黄文凤,等.61例血栓性血小板减少性紫癜患者的临床分析[J].北京大学学报（医学版）,2021,53(1):210-214.[9]中华医学会血液学分会血栓与止血组.血栓性血小板减少性紫癜诊断与治疗中国专家共识（2012 年版）[J].中华血液学杂志,2012,33(11):983-984.[10]Blennerhassett R,Curnow J,Pasalic L.Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults[J].Semin Thromb Hemost,2020,46(3):289-301.[11]Joly BS,Coppo P,Veyradier A.An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura[J].Expert Rev Hematol,2019,12(6):383-395.[12]?覶eneli ?魻,Y?覦lmaz S,Karaselek MA,et al.Outcome of Thrombotic Thrombocytopenic Purpura Patients: A Single-Center Experience[J].Turk J Haematol,2019,36(3):214-215. [13]Staley EM,Cao W,Pham HP,et al.Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura[J].Haematologica,2019,104(1):166-175.[14]Zheng XL,Vesely SK,Cataland SR,et al.ISTH guidelines for treatment of thrombotic thrombocytopenic purpura[J].J Thromb Haemost,2020,18(10):2496-2502.[15]王甜甜,曹俊杰,刘旭辉,等.结缔组织病继发的血栓性血小板减少性紫癜临床特点及治疗分析[J].中华全科医学,2022,20(4):598-601.[16]张怡慧,李英花.血栓性血小板减少性紫癜治疗及预后分析[J].临床与病理杂志,2019,39(5):1080-1084．[17]李惠平,卢鸿基,陶兢兢,等.以脑梗死起病的血栓性血小板减少性紫癜1例并文献复习[J].内科急危重症杂志,2020,26(2):173-176.[18]张潇然,刘博,王国兴.血栓性血小板减少性紫癜患者死亡危险因素分析[J].临床和实验医学杂志,2020,19(15):1578-1582.[19]何阳阳.40例血栓性血小板减少性紫癜临床特征和预后因素分析[D].南昌:南昌大学,2021.[20]Akaishi T,Kuroda H,Tateyama M,et al.Recurrent cerebral infarction synchronous with menorrhagia caused by endometrial stromal sarcoma[J].J Neurol Sci,2015,358(1-2):509-511.[21]杨义伟.原发性高血压肾病患者血清Hcy、vWF 和D-D检测的临床意义[J].放射免疫学杂志,2012,25(2):205-207．[22]de Lemos JA.Increasingly sensitive assays for cardiac troponins: a review[J].JAMA,2013,309(21):2262-2269.[23]Benhamou Y,Boelle PY,Baudin B,et al.Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center[J].J Thromb Haemost,2015,13(2):293-302.[24]贺阳,金钧,王俊,等.获得性血栓性血小板减少性紫癜患者的临床特征分析[J].中国全科医学,2019,22(36):4460-4464.